FFDS has demonstrated its potential in reducing circulating TG levels and angina frequency in patients with SCHD, which may be due to the active ingredients of FFDS acting on LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT. This evidence concerns the gene FABP1 and angina pectoris.